Maybe if the term significant was removed, the statement would have a shred of accuracy.
SCAMYDX360 revenue is declining. No one needs "Party Use" data labeled as pre-clinical.
SCammaDX, is out of stock, and 100% dependent on an external vendor creating the product. There has not be an increase in spend to support that product ever coming back.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.